Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4716-4724

  Chi, Sulene L ^a   Wahl, Miriam L ^a   Mowery, Yvonne M ^a   Shan, Siqing ^a   Mukhopadhyay, Somnath ^b   Hilderbrand, Susana C ^b   Kenan, Daniel J ^a   Lipes, Barbara D ^a   Johnson, Carrie E ^a   Marusich, Michael F ^a,c,d   Capaldi, Roderick A ^a,c,d   Dewhirst, Mark W ^a   Pizzo, Salvatore V ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^c Mitosciences LLC   (United States)

^d UNIVERSITY OF OREGON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; MONOCLONAL ANTIBODY; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CELL PH; CELL SURFACE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PURIFICATION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; HYDROLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT;

ADENOSINE TRIPHOSPHATE; ANGIOSTATINS; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; BIOMIMETIC MATERIALS; CATALYTIC DOMAIN; CATTLE; CHORIOALLANTOIC MEMBRANE; CORNEAL NEOVASCULARIZATION; ENDOTHELIAL CELLS; EPITOPE MAPPING; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MODELS, MOLECULAR; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, INBRED F344;

EID: 34250304605     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1094     Document Type: Article

References (36)

1. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-68.
2. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Huntingt) 2005;19:7-16.
3. Lenz HJ. Antiangiogenic agents in cancer therapy. Oncology (Huntingt) 2005;19:17-25.
4. Cao Y, Xue L. Angiostatin. Semin Thromb Hemost 2004;30:83-93.
5. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000;19:97-107.
6. Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A 2001;98:6656-61.
7. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96:2811-6.
8. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 2005;96:242-61.
9. Apoptosis and cell proliferation. Roche Molecular Biochemicals. 2nd ed. Mannheim (Germany): Boehringer Mannheim GmbH; 1998.
10. Arechaga I, Jones PC. Quick guide: ATP synthase. Curr Biol 2001;11:R117.
11. + -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol Cancer Res 2003;1:931-9.
12. Chi SL, Pizzo SV. Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res 2006;66:875-82.
13. + transporting ATP synthase on the surface of tumor cell lines. J Exp Med 1994;180:273-81.
14. Capaldi RA, Aggeler R. Mechanism of the F(1)F(0)-type ATP synthase, a biological rotary motor. Trends Biochem Sci 2002;27:154-60.
15. Moser TL, Stack MS, Wahl ML, Pizzo SV. The mechanism of action of angiostatin: can you teach an old dog new tricks? Thromb Haemost 2002;87:394-401.
16. Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 2004;4:153-6.
17. Wahl ML, Grant DS. Effects of microenvironmental extracellular pH and extracellular matrix proteins on angiostatin's activity and on intracellular pH. Gen Pharmacol 2002;35:277-85.
18. Wahl ML, Owen CS, Grant DS. Angiostatin induces intracellular acidosis and anoikis in endothelial cells at a tumor-like low pH. Endothelium 2002;9:205-16.
19. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
20. Aggeler R, Chicas-Cruz K, Cai SX, Keana JF, Capaldi RA Introduction of reactive cysteine residues in the e subunit of Escherichia coli F1 ATPase, modification of these sites with tetrafluorophenyl azide-maleimides, and examination of changes in the binding of the e subunit when different nucleotides are in catalytic sites. Biochemistry 1992;31:2956-61.
21. Marusich MF. Efficient hybridoma production using previously frozen splenocytes. J Immunol Methods 1988;114:155-9.
22. Grant DS, Kinsella JL, Kibbey MC, et al. Matrigel induces thymosin b4 gene in differentiating endothelial cells. J Cell Sci 1995;108:3685-94.
23. Burwick NR, Wahl ML, Fang J, et al. An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface. J Biol Chem 2005;280:1740-5.
24. Zheng J, Ramirez VD. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem Biophys Res Commun 1999;261:499-503.
25. Owen CS. Comparison of spectrum-shifting intracellular pH probes 5′(and 6′)-carboxy-10-dimethylamino-3-hydroxyspiro[7H-benzo[c] xanthene-7, 1′(3′H)-isobenzofuran]-3′-one and 2′,7′-biscarboxyethyl-5(and 6)-carboxyfluorescein. Anal Biochem 1992;204:65-71.
26. Wahl ML, Pooler PM, Briand P, Leeper DB, Owen CS. Intracellular pH regulation in a nonmalignant and a derived malignant human breast cell line. J Cell Physiol 2000;183:373-80.
27. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-50.
28. Popov E, Gavrilov I, Pozin E, Gabbasov Z. Multi-wavelength method for measuring concentration of free cytosolic calcium using the fluorescent probe Indo-1. Arch Biochem Biophys 1988;261:91-6.
29. White RR, Shan S, Rusconi CP, et al. Inhibition of rat corneal angiogenesis by a nuclease-specific RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A 2001;100:5028-33.
30. Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res 1999;59:5128-32.
31. DeMoraes ED, Fogler WE, Grant DS, et al. Recombinant human angiostatin (rhA): A Phase I clinical trial assessing safety pharmacokinetics and pharmacodynamics [abstract #10]. Am Soc Clin Oncol 2001;20:3a.
32. Boyer PD. The ATP synthase - a splendid molecular machine. Annu Rev Biochem 1997;66:717-49.
33. Pedersen PL, Amzel LM. ATP synthases. Structure, reaction center, mechanism, and regulation of one of natures most unique machines. J Biol Chem 1993;268:9937-40.
34. Shin YK, Yoo BC, Chang HJ, et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005;65:3162-70.
35. Nehls V, Drenckhahn D. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 1995;50:311-22.
36. Ribatti D, Nico B, Vacca A, Roncali L, Burri PH, Djonov V. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat Rec 2001;264:317-24.